Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4677176 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL2779265 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL25137537 | 0.92 | SLC6A9 (0.40) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL16922658 | 0.92 | MAPT (0.44) | SLC6A9HSD17B10TACR1MAPTALDH1A1 | |
| SCHEMBL17190336 | 0.92 | MAPT (0.44) | SLC6A9HSD17B10TACR1MAPTALDH1A1 | |
| SCHEMBL15444498 | 0.89 | SLC6A9 (0.38) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL12768265 | 0.89 | CHRM5 (0.40) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL8562008 | 0.88 | HSD17B10 (0.43) | HSD17B10POLBMAPK1L3MBTL1MAPT | |
| SCHEMBL11713448 | 0.88 | HSD17B10 (0.43) | HSD17B10POLBMAPK1L3MBTL1MAPT | |
| SCHEMBL17706711 | 0.88 | HSD17B10 (0.43) | HSD17B10POLBMAPK1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| US-20240189460-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-06-13 | — | — | US | claimed |
| WO-2024064969-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-03-28 | — | — | WO | claimed |
| US-11660356-B2 | Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2023-05-30 | — | — | US | claimed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | claimed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | claimed |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-05-12 | — | — | US | disclosed |
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2026-03-26 | — | — | US | disclosed |
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-4610269-A1 | UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE | 3B Pharmaceuticals GmbH (DE) | 2025-09-03 | — | — | EP | disclosed |
| EP-4590345-A2 | HIGH-PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | TRUSTEES OF TUFTS COLLEGE | 2024-06-27 | — | — | US | disclosed |
| EP-2954934-A1 | Conjugate comprising a neurotensin receptor ligand and use thereof | 3B Pharmaceuticals GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2954933-A1 | Conjugate comprising a neurotensin receptor ligand | 3B Pharmaceuticals GmbH (DE) | 2015-12-16 | — | — | EP | disclosed |
| US-20150299133-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3 B Pharmaceuticals GmbH | 2015-10-22 | — | — | US | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
| WO-2014086499-A1 | NEUROTENSIN RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2014-06-12 | — | — | WO | disclosed |
| EP-2740726-A1 | Neurotensin receptor ligands | 3B Pharmaceuticals GmbH (DE) | 2014-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083865-A1 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USE THEREOF | KLK3, FOLH1, PSMA1 | SLC6A9 1374/4885HSD17B10 1288/4885ALB 395/4885 |
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR1, PSMA1, KLK3 | SLC6A9 445/4885HSD17B10 4530/4885ALB 902/4885 |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | FAP, SSTR1, PSMA1 | SLC6A9 798/4885HSD17B10 4708/4885ALB 885/4885 |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | SLC6A9 1357/4885HSD17B10 4082/4885ALB 2301/4885 |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | GJB2, GJA1, GAP43 | SLC6A9 3051/4885HSD17B10 3433/4885ALB 2293/4885 |
| US-20150299133-A1 | NEUROTENSIN RECEPTOR LIGANDS | NTSR1, NTSR2, TACR3 | SLC6A9 432/4885HSD17B10 2490/4885ALB 2298/4885 |
| US-20240207292-A1 | BORONIC ACID COMPOUNDS, COMPOSITIONS AND METHODS | BCL6B, BCL6, BTD | SLC6A9 705/4885HSD17B10 2957/4885ALB 614/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | SLC6A9 1573/4885HSD17B10 3900/4885ALB 2165/4885 |
| US-20240189460-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | SLC6A9 739/4885HSD17B10 4709/4885ALB 2816/4885 |
| US-12622984-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR2, SSTR1, SSTR3 | SLC6A9 682/4885HSD17B10 887/4885ALB 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.